Table 2.
Summary of FAK signaling inhibitors in clinical trials.
| Name | Target/Mode of Action | Development Phase | Condition or Disease | Status | Trial Identifier |
|---|---|---|---|---|---|
| GSK2256098 | ATP-competitive kinase inhibitor | Phase II | Pancreatic cancer; adenocarcinoma | Active, not recruiting | NCT02428270 |
| Phase I | Mesothelioma; solid tumors | Completed | NCT01138033 NCT01938443 | ||
| Phase II | Meningioma | Suspended | NCT02523014 | ||
| BI 853520 | ATP-competitive kinase inhibitor | Phase I | Advanced or metastatic cancers | Completed |
NCT01335269 NCT01905111 |
| PF-562271 (VS-6062) |
ATP-competitive kinase inhibitor | Phase I | Head and neck cancer; prostatic cancer; pancreatic cancer | Completed | NCT00666926 |
| PND-1186 (VS-4718) |
ATP-competitive kinase inhibitor | Phase I | Pancreatic cancer; non-hematologic or metastatic cancers; leukemia | Terminated or withdrawn |
NCT02651727 NCT01849744 NCT02215629 |
| Defactinib (VS-6063; PF-04554878) |
ATP-competitive kinase inhibitor | Phase I | Malignant pleural mesothelioma | Not yet recruiting | NCT04201145 |
| Phase I | NSCLC; solid tumors; low grade serous ovarian cancer; colorectal cancer | Recruiting | NCT03875820 | ||
| Phase I/II | Ovarian cancer | Recruiting | NCT03287271 | ||
| Phase I/II | Carcinoma; NSCLC; mesothelioma; pancreatic cancer | Recruiting | NCT02758587 | ||
| Phase II | Pancreatic ductal adenocarcinoma | Recruiting | NCT03727880 | ||
| Phase I | Advanced solid tumors; pancreatic cancer | Active, not recruiting | NCT02546531 | ||
| Phase II | Cancers with NF2 genetic changes (advanced lymphoma; advanced solid cancers; hematopoietic cancers, etc.) | Active, not recruiting | NCT04439331 | ||
| Phase II | Patients with KRAS mutations (NSCLC; lung cancer) | Completed | NCT01951690 | ||
| Phase I | Ovarian cancer | Completed | NCT01778803 | ||
| Phase I | Non-hematologic cancers | Completed | NCT01943292 | ||
| Phase I | Advanced non-hematologic malignancies | Completed | NCT00787033 | ||
| Phase I | Healthy subjects | Completed | NCT02913716 | ||
| Phase II | Malignant pleural mesothelioma | Terminated | NCT02004028 | ||
| Phase I | Epithelial ovarian cancer | Terminated | NCT02943317 | ||
| Phase II | Malignant pleural mesothelioma | Terminated | NCT01870609 | ||
| Phase I | Relapsed malignant mesothelioma | Terminated | NCT02372227 |
NF2, neurofibromatosis 2; NSCLC, non-small-cell lung cancer; KRAS, Kirsten rat sarcoma 2 viral oncogene homolog.